Research programme: HDAC1/2 inhibitors - Regenacy Pharmaceuticals

Drug Profile

Research programme: HDAC1/2 inhibitors - Regenacy Pharmaceuticals

Alternative Names: ACY 957; ACY-1035; RCY-1305

Latest Information Update: 24 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Acetylon Pharmaceuticals
  • Developer Regenacy Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Erythropoiesis stimulants; Fetal haemoglobin stimulants; HDAC1 protein inhibitors; HDAC2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Beta-thalassaemia; Cancer; Psychiatric disorders; Sickle cell anaemia

Most Recent Events

  • 04 Dec 2016 Preclinical development is ongoing fpr Sickle cell anaemia and Beta-Thalassemia in USA
  • 04 Dec 2016 Pharmacodynamics data from a preclinical trial in Sickle cell anaemia and Beta-Thalassemia released by Acetylon Pharmaceuticals
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Beta-thalassaemia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top